News

Biologic DMARDs Do Not Prevent Spinal Fractures in AS Patients, Swedish Study Shows

Use of biological disease-modifying antirheumatic drugs (bDMARDs) does not prevent spinal fractures in patients with ankylosing spondylitis, according to a Swedish population-based study. Findings from the study, “Do biological disease-modifying antirheumatic drugs reduce the spinal fracture risk related to ankylosing spondylitis? A longitudinal multiregistry matched cohort study,”…

Top-line Data Awaited in Phase 2b Trial of Alternative to Naproxen as Painkiller

Antibe Therapeutics has fully enrolled a trial comparing the gastrointestinal safety of investigative compound ATB-346 with naproxen, a nonsteroidal anti-inflammatory drug (NSAID). The Phase 2b trial is running as scheduled, and the company plans to release top-line data within six weeks. Naproxen, sold under the brand names Aleve, Naprosyn, and others, is one of the…